Agile bristles after FDA's third snub, promising a fight for its contraceptive
Agile Therapeutics is starting to get testy after suffering yet another snub from the FDA, announcing this morning that it simply doesn’t agree with the regulators’ assertion that its contraception patch is faulty.
The company is strapping on boxing gloves over the matter, as the FDA’s requests could sink the company financially — unless it finds new ways to cover the bills.
Agile’s once-weekly, low-dose contraceptive patch called Twirla is a combination hormonal patch that contains ethinyl estradiol and levonorgestrel.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.